ProteinQure

ProteinQure is a computational drug discovery company focused on designing peptide-based therapeutics. Its platform blends physics-based molecular modeling with machine learning to address a long-standing problem in biotech: peptides are attrACTive drug candidates, but engineering them to be stable, specific, and drug-like has historically been difficult. ProteinQure positions its Technology as a way to generate and refine small, exotic peptide ligands that behave more like conventional small-molecule drugs while retAIning the selectivity of biologics.

What it does

The core offering is a peptide discovery platform that uses High-Performance Computing, molecular simulation, and Machine Learning to predict and optimize ligand candidates. Because these methods are structure-driven rather than purely data-driven, the company says its workflows can reduce reliance on large experimental datasets. The platform is aimed at identifying peptide ligands with improved specificity and drug-like pRoPErties, and at enabling structure-based design of novel binders.

Key capabilities

• Physics-Informed design: Combines molecular simulation with machine learning to model peptide behavior and binding.
• Structure-based ligand discovery: Supports design of novel peptide ligands using structural and physical modeling rather than exclusively large datasets.
• Lead optimization: The company reports optimizing lead compounds with relatively few experimental data points, though specific figures should be confirmed directly.
• Payload delivery focus: EmphASIzes peptide-based delivery of next-generation therapeutic payloads such as nucleotides, siRNA, and radioisotopes.
• Wet-lab validation: Pairs computational predictions with experimental validation to test designed compounds.

Who it is for

ProteinQure is primarily built for phArmaceutical and biotechnology organizations engaged in peptide drug discovery, as well as research groups exploring peptide-mediated delivery of therapeutic payloads. Its collaboration history suggests it works with established drug developers rather than indiVidual consumers or casual users. Academic or translational researchers with interest in computational peptide design may find the underlying APProach relevant, but access is likely partnership-driven.

How to get started

There is no self-serve signup flow described publicly. Interested parties would typically begin by contacting the company through its official website to discuss research or collaboration opportunities. Because the platform is oriented toward industry Partnerships, onboarding likely involves scoping a discovery project rather than subscribing to software.

Pricing and access caveat

ProteinQure does not appear to publish Standard pricing, and its services are structured around partnerships and internal pipeline development. Pricing, access terms, and service scope may vary and should be verified directly with the company. Details such as veRSIon numbers or licensing tiers are not publicly established and may change over time.